Holen Sie sich die Stockscreener-App
0.7086
3.23%
0.0222
Handel nachbörslich:
.73
0.0214
+3.02%
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jasper Therapeutics Inc (JSPRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jasper Therapeutics Inc (JSPRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan
Jasper (JSPR) Latest: Gains 3.59% to Reach $0.72 in Latest Trading; Price Levels: Price Remains Between $0.68 Support and $0.76 Resistance under the Current SnapshotLong Setup Ideas - vinanet.vn
Wenru Song Net Worth (2026) - GuruFocus
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc (JSPR) Stock News Today - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives? - Kalkine Media
JSPR Q1 2026 Earnings: Loss Narrowly Beats Estimates, Shares Surge 12.95%Dividend Increase Stocks - vinanet.vn
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirt - The National Law Review
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst - TipRanks
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know - TipRanks
JSPR Q2'26 Earnings: EPS estimate is (0.25) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors - marketscreener.com
Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale - Stock Titan
Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director - Stock Titan
Jasper Therapeutics (JSPR) awards 7,500 stock options to board director - Stock Titan
Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director - Stock Titan
Jasper Therapeutics (JSPR) grants director option for 7,500 shares - stocktitan.net
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan - tipranks.com
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes - Stock Titan
Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs - TipRanks
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Slips to $0.62 as Stock Tests Key SupportRange Breakout - vinanet.vn
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News - TradingKey
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Income Statement - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.695|Chg%:+0.006 - TradingKey
Jasper Therapeutics (JSPR) Edges Higher Near Key Support LevelMoney Flow - vinanet.vn
JSPR|Jasper Therapeutics Inc|Price:0.690|Chg%:+0.002 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.716|Chg%:+0.025 - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Cash Flow - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.650|Chg%:-0.038 - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):